


PHARMACEUTICAL 2023

PROCYON CORP Rank 122 of 446

PROCYON







PHARMACEUTICAL 2023

PROCYON CORP Rank 122 of 446

PROCYON

The relative strengths and weaknesses of PROCYON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROCYON CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 158% points. The greatest weakness of PROCYON CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 177%, being 134% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,585
Cost of Goods Sold	1,357
Intangible Assets	17
Liabilities, Current	643
Liabilities, Non-Current	491
Other Assets	1,047
Other Compr. Net Income	0
Other Expenses	1,987
Other Liabilities	0
Other Net Income	1.8
Other Revenues	4,842
Property and Equipment	154
Research and Development	0
Selling, General and Administrative Expense	1,711

Output Variable	Value in 1000 USD
Assets	3,802
Liabilities	1,135
Expenses	5,054
Revenues	4,842
Stockholders Equity	2,668
Net Income	-210
Comprehensive Net Income	-210
Economic Capital Ratio	177%

